In accordance with the infiltrating preference of MARCO+ TAMs in ICB non‐responders, the bulk RNA‐seq cohort also indicated a correlation between greater levels of MARCO+ TAMs and significantly unfavorable prognosis in RCC patients with ICB treatments (overall survival: p = 0.006; progression‐free survival: p = 0.03) (Figure3A; and Table S3, Supporting Information). This evidence concerns the gene MARCO and renal cell adenocarcinoma.